X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Boehringer Ingelheim and Enara Bio Partner on Cancer Immunotherapies

    Boehringer Ingelheim and Enara Bio Partner on Cancer Immunotherapies

    Pfizer’s new partnership focuses on digitising clinical trials

    Pfizer Invests $120 Million in Biotechnology Innovation

    DCGI nod to Serum-Oxford covid-19 vaccine for phase 2, 3 clinical trials in India

    Baxter Biopharma Announces Sterile Manufacturing Agreement for Novavax COVID-19 Vaccine

    Pfizer and BioNTech Announce Agreement with the UK 30 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2

    Baxter Biopharma Announces Sterile Manufacturing Agreement for Novavax COVID-19 Vaccine

    Servier and X-Chem Announce Drug Discovery Collaboration in Neurological Diseases

    Servier and X-Chem Announce Drug Discovery Collaboration in Neurological Diseases

    KORSCH AND MEDELPHARM Partner to Introduce R&D Equipment Portfolio

    KORSCH AND MEDELPHARM Partner to Introduce R&D Equipment Portfolio

    Fujifilm and the Center for Advanced Biological Innovation Announce 76 million USD in Funding for Manufacturing and Innovation Center

    Fujifilm and the Center for Advanced Biological Innovation Announce 76 million USD in Funding for Manufacturing and Innovation Center

    Cytiva Delivers Modular Biologics Factory to Lonza

    Cytiva Delivers Modular Biologics Factory to Lonza

    Thermo Fisher Scientific Launches Controlled-Rate Freezers for Optimal Sample Protection

    Thermo Fisher Scientific Launches Controlled-Rate Freezers for Optimal Sample Protection

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Boehringer Ingelheim and Enara Bio Partner on Cancer Immunotherapies

    Boehringer Ingelheim and Enara Bio Partner on Cancer Immunotherapies

    Pfizer’s new partnership focuses on digitising clinical trials

    Pfizer Invests $120 Million in Biotechnology Innovation

    DCGI nod to Serum-Oxford covid-19 vaccine for phase 2, 3 clinical trials in India

    Baxter Biopharma Announces Sterile Manufacturing Agreement for Novavax COVID-19 Vaccine

    Pfizer and BioNTech Announce Agreement with the UK 30 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2

    Baxter Biopharma Announces Sterile Manufacturing Agreement for Novavax COVID-19 Vaccine

    Servier and X-Chem Announce Drug Discovery Collaboration in Neurological Diseases

    Servier and X-Chem Announce Drug Discovery Collaboration in Neurological Diseases

    KORSCH AND MEDELPHARM Partner to Introduce R&D Equipment Portfolio

    KORSCH AND MEDELPHARM Partner to Introduce R&D Equipment Portfolio

    Fujifilm and the Center for Advanced Biological Innovation Announce 76 million USD in Funding for Manufacturing and Innovation Center

    Fujifilm and the Center for Advanced Biological Innovation Announce 76 million USD in Funding for Manufacturing and Innovation Center

    Cytiva Delivers Modular Biologics Factory to Lonza

    Cytiva Delivers Modular Biologics Factory to Lonza

    Thermo Fisher Scientific Launches Controlled-Rate Freezers for Optimal Sample Protection

    Thermo Fisher Scientific Launches Controlled-Rate Freezers for Optimal Sample Protection

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Asia

InDex Pharmaceuticals gets new patent granted in Japan

Yuvraj_pawp by Yuvraj_pawp
13th September 2017
in Asia, News

InDex Pharmaceuticals Holding AB (publ) today announced that a new method of use patent for the drug candidate cobitolimod has been granted by the Japan Patent Office. The patent provides additional protection for the use of certain dosage regimens of cobitolimod for treating chronic active ulcerative colitis in patients that are not responding or are intolerant to anti-inflammatory therapy.

The patent, entitled Method for prevention of colectomy (patent number 6193248), was filed in 2012 and will provide an exclusivity period until November 2032, with the possibility of up to 5 years term extension after market approval.

“We are very pleased with the granting of this patent by the Japan Patent Office, which again confirms that cobitolimod is a unique and innovative asset for treating ulcerative colitis,” said Peter Zerhouni, CEO of InDex Pharmaceuticals. “This patent further strengthens and extends our intellectual property position for cobitolimod in Japan, which is the second largest individual pharmaceutical market in the world.”

A corresponding patent was granted in the US in November 2016, and corresponding patent applications have also been filed in Europe and Canada and are being diligently prosecuted to grant.

 

For more information:
Peter Zerhouni, CEO
Phone: +46 8 508 847 35
E-mail: peter.zerhouni@indexpharma.com

Cobitolimod in brief
Cobitolimod is a new type of drug that can help patients with moderate to severe ulcerative colitis back to a normal life. It is a so-called Toll-like receptor 9 (TLR9) agonist, that can provide an anti-inflammatory effect locally in the large intestine, which may induce mucosal healing and relief of the clinical symptoms in ulcerative colitis. Cobitolimod has achieved clinical proof-of-concept in moderate to severe active ulcerative colitis, with a very favorable safety profile. Data from four placebo-controlled clinical trials indicate that cobitolimod has statistically significant effects on those endpoints that are most relevant in this disease, both from a regulatory and clinical perspective. These endpoints include the key clinical symptoms such as blood in stool, number of stools, and mucosal healing, respectively. Cobitolimod is also known as Kappaproct® and DIMS0150.

 

InDex Pharmaceuticals in brief
InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s foremost asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe active ulcerative colitis – a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases.

InDex is based in Stockholm, Sweden. The company’s shares are traded on Nasdaq First North Stockholm. Redeye AB is the company’s Certified Adviser. For more information, please visit www.indexpharma.com

Tags: Middle East & South Asia
Previous Post

The Maestro Pro and Maestro Edge Platforms Introduced By Axion BioSytems

Next Post

Novartis' Cosentyx sets new benchmark in psoriasis with robust 5-year sustained phase III efficacy & safety data

Related Posts

CPhI & P-MEC China gives a glimpse of the success returning pharma events will deliver in 2021
Manufacturing

CPhI & P-MEC China gives a glimpse of the success returning pharma events will deliver in 2021

20th January 2021
Tessa Therapeutics Receives PRIME Designation from European Medicines Agency for CD30 CAR-T Therapy
Middle East and South Asia

Tessa Therapeutics Receives PRIME Designation from European Medicines Agency for CD30 CAR-T Therapy

19th January 2021
Pfizer’s new partnership focuses on digitising clinical trials
Drug Development

Pfizer Invests $120 Million in Biotechnology Innovation

19th January 2021
Bharat Biotech signs agreement with Precisa Medicamentos to supply Covaxin to Brazil
Manufacturing

Bharat Biotech signs agreement with Precisa Medicamentos to supply Covaxin to Brazil

19th January 2021
DHL expands pharma capabilities in South Africa
Featured

DHL expands pharma capabilities in South Africa

19th January 2021
Dr Reddy's Lab gets DCGI nod for Sputnik Phase 2 & 3 trials
News

Algeria has become the first country in Africa to register Sputnik V vaccine

19th January 2021
Next Post

Novartis' Cosentyx sets new benchmark in psoriasis with robust 5-year sustained phase III efficacy & safety data

Latest News

CPhI & P-MEC China gives a glimpse of the success returning pharma events will deliver in 2021
Manufacturing

CPhI & P-MEC China gives a glimpse of the success returning pharma events will deliver in 2021

20th January 2021
Boehringer Ingelheim and Enara Bio Partner on Cancer Immunotherapies
Drug Development

Boehringer Ingelheim and Enara Bio Partner on Cancer Immunotherapies

19th January 2021
Tessa Therapeutics Receives PRIME Designation from European Medicines Agency for CD30 CAR-T Therapy
Middle East and South Asia

Tessa Therapeutics Receives PRIME Designation from European Medicines Agency for CD30 CAR-T Therapy

19th January 2021
Pfizer’s new partnership focuses on digitising clinical trials
Drug Development

Pfizer Invests $120 Million in Biotechnology Innovation

19th January 2021
Bharat Biotech signs agreement with Precisa Medicamentos to supply Covaxin to Brazil
Manufacturing

Bharat Biotech signs agreement with Precisa Medicamentos to supply Covaxin to Brazil

19th January 2021
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In